High S phase kinase‑associated protein 2 expression is a potential prognostic biomarker for glioma

Zhang, Cheng; Cai, Hong‐Qing; Zhang, Minjie; Zhong, Yi; He, Jié; Yuan, Qing; Hao, Jia‐Jie; Wang, Ming‐Rong; Wan, Jinghai

doi:10.3892/ol.2020.11818

Cited by 6 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S1, Supplemental Digital Content 2, http://links.lww.com/AIMM/A409). 15,18 We found that PDPN expression was positively associated with IDH wild-type status, TERT promoter mutation status, and ATRX retention status (P < 0.001, Fig. 2A).…”

Section: Pdpn Expression Is Associated With the Cns5 Who Classificationmentioning

confidence: 89%

“…The telomerase reverse transcriptase ( TERT ) promoter region was amplified with the forward primer 5′-TTCCAGCTCCGCCTCCT-3′ and the reverse primer 5′-GCGCTGCCTGAAACTCG-3′. Polymerase chain reaction procedures and DNA sequencing were performed as previously described 18…”

Section: Methodsmentioning

confidence: 99%

“…Polymerase chain reaction procedures and DNA sequencing were performed as previously described. 18 Cell Culture and Small-interfering RNA (siRNA) Transfection…”

Section: Dna Extraction and Sanger Sequencingmentioning

confidence: 99%

See 2 more Smart Citations

Overexpression of Podoplanin Predicts Poor Prognosis in Patients With Glioma

Zhang

Yuan

et al. 2023

Applied Immunohistochemistry &Amp; Molecular Morphology

Self Cite

View full text Add to dashboard Cite

High podoplanin (PDPN) expression correlates with poor prognosis in various cancers. However, the expression and clinical value of PDPN in glioma are unclear. In this study, PDPN expression was compared in 227 glioma tissues and 22 paired non-neoplastic tissues, and its association with prognostic factors was statistically analyzed. The effect of PDPN knockdown on the proliferation ability of glioma cells (U87MG and U118MG cell lines) was assessed along with the underlying molecular mechanism. Overexpression of PDPN was observed in the majority of glioma tissues compared with the expression in normal tissues. PDPN overexpression was positively correlated with IDH wild-type status, TERT promoter mutation status, and ATRX retention status, and was negatively correlated with 1p/ 19q codeletion status. The expression level of PDPN was positively correlated with the glioma grade in the diffuse astrocytoma, IDH wild-type. High PDPN expression was also negatively correlated with survival in astrocytoma patients with IDH mutation or wild-type and in glioblastoma patients with IDH wild-type. Grade, radiochemotherapy, and PDPN overexpression emerged as independent indicators for a poor prognosis of glioma patients. PDPN knockdown suppressed proliferation and reduced p-Akt and p-mTOR protein expression in glioma cells. PDPN is a potential biomarker or therapeutic target for glioma that is closely associated with tumor grade and poor prognosis, which may play a role in enhancing cell proliferation via Akt/mTOR signaling.

show abstract

Section: Pdpn Expression Is Associated With the Cns5 Who Classificationmentioning

confidence: 89%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Overexpression of Podoplanin Predicts Poor Prognosis in Patients With Glioma

Zhang

Yuan

et al. 2023

Applied Immunohistochemistry &Amp; Molecular Morphology

Self Cite

View full text Add to dashboard Cite

show abstract

“…They confirmed that downregulation of SKP2 could significantly reduce the migration and invasion ability of oral squamous cell carcinoma cells. In several tumors, such as breast cancer, osteosarcoma, and glioblastoma, overexpression of SKP2 was associated with poor prognosis [ 6 , 37 , 38 ]. Based on our pan-cancer study, increased SKP2 was a risk factor for the prognosis (OS, DSS, DFI, and/or PFI) of individuals with one of ten types of cancers — ACC, KICH, KIRP, LGG, LIHC, MESO, PRAD, SKCM, THCA, and UVM — while it predicted a favorable prognosis in READ, THYM, and OV patients.…”

Section: Discussionmentioning

confidence: 99%

Gene S-phase kinase associated protein 2 is a novel prognostic marker in human neoplasms

Huang

Zhou

2023

BMC Med Genomics

View full text Add to dashboard Cite

Background Neoplasms are a series of diseases affecting human health. Prognostic and tumor status–related markers for various tumors should be identified. Methods Based on 19,515 samples from multiple sources, for the first time, this study provided an overview of gene S-phase kinase associated protein 2 (SKP2) in pan-cancer. Differential SKP2 expression in multiple comparison groups was identified by the Kruskal–Wallis test and Wilcoxon rank-sum test. The prognosis significance of SKP2 in individuals with neoplasm was evaluated through univariate Cox regression analysis and Kaplan-Meier curves. The area under the curve was utilized to detect the accuracy of SKP2 in predicting cancer status. Spearman’s rank correlation coefficients were calculated in all correlation analyses. Gene set enrichment analysis was used to identify essential signaling pathways of SKP2 in human neoplasms. Results The study disclosed the upregulated SKP2 expression in 15 neoplasms and decreased SKP2 expression in three cancers (p < 0.05). The transcription factor Forkhead Box M1 may contribute to the increased expression levels of SKP2 in certain tumors. Over-expressed SKP2 represented a risk factor for the prognosis of most cancer patients (hazard ratio > 1, p < 0.05). SKP2 expression made it feasible to distinguish neoplasm and control tissues of 21 neoplasms (sensitivity = 0.79, specificity = 0.87, area under the curve = 0.90), implying its potential in screening a series of neoplasms. Further, the research revealed the close association of SKP2 expression with DNA methyltransferases, mismatch repair genes, microsatellite instability, tumor mutational burden, neoantigen count, and immunity. Conclusions SKP2 plays an essential role in multiple neoplasms and may serve as a marker for treating and identifying these neoplasms.

show abstract

“…Anti-EGFRvIII antibody (working solution, ZA-0643, ZSGB-BIO) and Anti-ATRX antibody (1:500, ab188027, abcam) was used to detect EGFRvIII and ATRX expression. Sanger sequencing for detecting TERT promoter mutations and immunohistochemistry (IHC) was performed as described previously [ 4 , 5 ].…”

Section: Methodsmentioning

confidence: 99%

Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma

et al. 2023

Self Cite

View full text Add to dashboard Cite

Purpose To explore the potential pathogenesis and clinical features of second primary glioblastoma (spGBM) following first primary renal cell carcinoma (fpRCC). Methods Patients with spGBM after fpRCC were enrolled from our institution and the SEER dataset. Sanger sequencing, whole genome sequencing, and immunehistochemistry were used to detect molecular biomarkers. Results Four and 122 cases from our institution and the SEER dataset, respectively, were collected with an overall median age of 69 years at spGBM diagnosis following fpRCC. The median interval time between fpRCC and spGBM was 50.7 months and 4 years, for the four and 122 cases respectively. The median overall survival time was 11.2 and 6.0 months for the two datasets. In addition, spGBM patients of younger age (< 75 years) or shorter interval time (< 1 year) had favorable prognosis (p = 0.081 and 0.05, respectively). Moreover, the spGBM cases were molecularly classified as TERT only paired with TP53 mutation, PIK3CA mutation, EGFR alteration, low tumor mutation burden, and stable microsatellite status. Conclusions This is the first study to investigate the pathogenesis and clinical features of spGBM following spRCC. We found that spGBMs are old-age related, highly malignant, and have short survival time. Moreover, they might be misdiagnosed and treated as brain metastases from RCC. Thus, the incidence of spGBMs after fpRCC is underestimated. Further studies are needed to investigate the underlying molecular mechanisms and clinical biomarkers for the development of spGBM following fpRCC.

show abstract

High S phase kinase‑associated protein 2 expression is a potential prognostic biomarker for glioma

Cited by 6 publications

References 49 publications

Overexpression of Podoplanin Predicts Poor Prognosis in Patients With Glioma

Overexpression of Podoplanin Predicts Poor Prognosis in Patients With Glioma

Gene S-phase kinase associated protein 2 is a novel prognostic marker in human neoplasms

Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma

Contact Info

Product

Resources

About